Anthrax vaccines

About: Anthrax vaccines is a research topic. Over the lifetime, 685 publications have been published within this topic receiving 21495 citations.

Mixed anthrax vaccine

Abstract: FIELD: medicine. SUBSTANCE: vaccine has living spores of noncapsule strain of Bac. anthracis aeAEe and protective antigen of Bac. anthracis. A single dose of commercial variant of vaccine has: living spores of strain Bac. anthracis aeAEe - 40-60 mln; protective antigen of Bac. anthracis - 30-40 ea 50 and aluminium hydroxide gel 2.5 mg, not above, where ea 50 - mean effective immunizing unit for albino mice. Vaccination is carried out one time per a year, expressing immunity is formed in 7-10 days. Immunization at antibiotic therapy background is possible. EFFECT: improved quality of vaccine. 5 tblt

Recurrent, localized urticaria and erythema multiforme: a review and management of cutaneous anthrax vaccine-related events.

Abstract: The October 2001 domestic anthrax attacks affected 22 people, resulting in 5 fatalities. The added global terrorist threats have created an increasing need for homeland protection, as well as protection of our widely deployed forces battling terrorism. It is now relevant for physicians to be familiar with both clinical anthrax and adverse vaccine-related events associated with the resumption of the anthrax vaccine program. Dermatologists played a lead role in the initial response to the anthrax attack. We must be the lead providers most familiar with the cutaneous reactions that may be seen with the preventive vaccination. This article reviews the latest recommended evaluation and management of anthrax vaccine adverse events.

Perceptions and Practices towards Anthrax in Selected Agricultural Communities in Arua District, Uganda.

Abstract: Background Anthrax is globally recognized as an important public health and economic challenge in many agricultural communities. A cross-sectional study was conducted in three subcounties in Arua district to assess the community's awareness, cultural norm, and practices regarding anthrax. This followed a report of active cases of human cutaneous anthrax in the district. Methods The study was conducted in subcounties of Pawor, Rigbo, and Rhino Camp, Arua district, using focus group discussion. Results The affected communities had limited knowledge about anthrax, especially its clinical manifestation and modes of transmission both in humans and animals. The community also had no knowledge of the anthrax vaccine or treatment and where they can be accessed from. Poor practices associated with anthrax outbreaks included poor disposal of carcasses and ruminal wastes, occupational hazards (butchers, slaughter men, and herdsmen), consumption of meat from infected animals, communal herding, and cultural norms encouraging consumption of dead animals. Conclusion This study shows that there is a knowledge gap about anthrax among the people in the affected communities. Key drivers for the anthrax outbreak such as poor cultural beliefs and practices and wildlife-livestock-human interactions were observed in all the three subcounties studied. All these findings could imply a high risk of outbreak of anthrax in Arua and Ugandan agricultural communities where the public health programs are less standardized and less effective.

Epitope targeted anthrax vaccine

Abstract: Anthrax vaccine compositions comprise a segment of a PA toxin protein that stimulates a B cell immune response specific for a defined epitope on the protective antigen of B. anthracis, a pharmaceutical excipient and optionally, one or more other protein segments comprising epitopes that augment the B cell response by stimulating a T cell immune response. The pharmaceutical compositions are useful for vaccinating individuals so as to confer protection from disease caused by B. anthracis including anthrax disease resulting from anthrax spore inhalation.